{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:54:05Z","timestamp":1791982445012,"version":"4.4.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.amjcard.2026.07.022","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:57:57Z","timestamp":1785884277000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Pulmonary Arterial Hypertension-Targeted Therapy for Pulmonary Hypertension Associated With Left Heart Disease: Bayesian and Frequentist Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1016","volume":"278","author":[{"given":"Yuko","family":"Kiyohara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina M.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Katzianer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T.","family":"Siuba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Chaisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Correa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giovanna","family":"Trivieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai Hong Wilson","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Miyashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2026.07.022_bib0001","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/eurheartj\/ehv512","article-title":"Left ventricular heart failure and pulmonary hypertension","volume":"37","author":"Rosenkranz","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2026.07.022_bib0002","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2026.07.022_bib0003","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.jacc.2009.01.004","volume":"53","author":"McLaughlin","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2026.07.022_bib0004","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01897-2018","article-title":"Pulmonary hypertension due to left heart disease","volume":"53","author":"Vachi\u00e9ry","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.amjcard.2026.07.022_bib0005","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1161\/HYPERTENSIONAHA.119.14330","article-title":"Pulmonary hypertension due to left heart disease: diagnosis, pathophysiology, and therapy","volume":"75","author":"Al-Omary","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.amjcard.2026.07.022_bib0006","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01325-2024","article-title":"Treatment algorithm for pulmonary arterial hypertension","volume":"64","author":"Chin","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.amjcard.2026.07.022_bib0007","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.amjcard.2026.07.022_bib0008","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.chest.2018.11.030","article-title":"Therapy for pulmonary arterial hypertension in adults: update of the CHEST guideline and Expert Panel Report","volume":"155","author":"Klinger","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.amjcard.2026.07.022_bib0009","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/sim.6381","article-title":"Predictive distributions for between-study heterogeneity and simple methods for their application in Bayesian meta-analysis","volume":"34","author":"Turner","year":"2015","journal-title":"Stat Med"},{"key":"10.1016\/j.amjcard.2026.07.022_bib0010","series-title":"Bayesian approaches to clinical trials and health-care evaluation","author":"Spiegelhalter","year":"2008"},{"key":"10.1016\/j.amjcard.2026.07.022_bib0011","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1214\/08-AOAS191","article-title":"A weakly informative default prior distribution for logistic and other regression models","volume":"2","author":"Gelman","year":"2008","journal-title":"Ann Appl Stat"},{"key":"10.1016\/j.amjcard.2026.07.022_bib0012","doi-asserted-by":"crossref","DOI":"10.18637\/jss.v080.i01","article-title":"Brms: an R package for Bayesian multilevel models using Stan","volume":"80","author":"B\u00fcrkner","year":"2017","journal-title":"J Stat Softw"},{"key":"10.1016\/j.amjcard.2026.07.022_bib0013","doi-asserted-by":"crossref","DOI":"10.18637\/jss.v076.i01","article-title":"Stan: a probabilistic programming language","volume":"76","author":"Carpenter","year":"2017","journal-title":"J Stat Softw"},{"key":"10.1016\/j.amjcard.2026.07.022_bib0014","unstructured":"Schwarzer G General package for meta-analysis [R package meta version 8.0-2. Available at: https:\/\/CRAN.R-project.org\/package=meta. Accessed on April 14, 2025."},{"key":"10.1016\/j.amjcard.2026.07.022_bib0015","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.amjcard.2026.07.022_bib0016","series-title":"Cochrane handbook for systematic reviews of interventions","year":"2019"},{"key":"10.1016\/j.amjcard.2026.07.022_bib0017","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.123.011381","article-title":"Macitentan for heart failure with preserved or mildly reduced ejection fraction and pulmonary vascular disease: results of the SERENADE randomized clinical trial and open-label extension study","volume":"18","author":"Shah","year":"2025","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.amjcard.2026.07.022_bib0018","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1161\/CIRCULATIONAHA.124.069340","article-title":"Tadalafil for treatment of combined postcapillary and precapillary pulmonary hypertension in patients with heart failure and preserved ejection fraction: a randomized controlled phase 3 study","volume":"150","author":"Hoeper","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2026.07.022_bib0019","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/ejhf.2527","article-title":"Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo-controlled multicentre trial","volume":"24","author":"Cooper","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2026.07.022_bib0020","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01886-2017","article-title":"Macitentan in pulmonary hypertension due to left ventricular dysfunction","volume":"51","author":"Vachi\u00e9ry","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.amjcard.2026.07.022_bib0021","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/eurheartj\/ehx700","article-title":"Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial","volume":"39","author":"Bermejo","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2026.07.022_bib0022","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1093\/eurheartj\/ehv336","article-title":"Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial","volume":"36","author":"Hoendermis","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2026.07.022_bib0023","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000107791","article-title":"Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension\u2013a multi-center randomized study","volume":"109","author":"Kaluski","year":"2008","journal-title":"Cardiology"},{"key":"10.1016\/j.amjcard.2026.07.022_bib0024","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1161\/CIRCULATIONAHA.107.716373","article-title":"Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension","volume":"116","author":"Lewis","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2026.07.022_bib0025","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijcard.2018.09.043","article-title":"Pulmonary vasodilator therapies are of no benefit in pulmonary hypertension due to left heart disease: a meta-analysis","volume":"273","author":"Cao","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjcard.2026.07.022_bib0026","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ejhf.47","article-title":"Additional use of a phosphodiesterase 5 inhibitor in patients with pulmonary hypertension secondary to chronic systolic heart failure: a meta-analysis","volume":"16","author":"Wu","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2026.07.022_bib0027","doi-asserted-by":"crossref","first-page":"488","DOI":"10.14740\/jocmr3008w","article-title":"Phosphodiesterase-5 inhibitors improve clinical outcomes, exercise capacity and pulmonary hemodynamics in patients with heart failure with reduced left ventricular ejection fraction: a meta-analysis","volume":"9","author":"De Vecchis","year":"2017","journal-title":"J Clin Med Res"},{"key":"10.1016\/j.amjcard.2026.07.022_bib0028","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/hr.2015.73","article-title":"Comparative effectiveness of sildenafil for pulmonary hypertension due to left heart disease with HFrEF","volume":"38","author":"Jiang","year":"2015","journal-title":"Hypertens Res"},{"key":"10.1016\/j.amjcard.2026.07.022_bib0029","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1056\/NEJMct0904473","article-title":"Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension","volume":"361","author":"Archer","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2026.07.022_bib0030","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","article-title":"Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study","volume":"358","author":"Channick","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2026.07.022_bib0031","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2026.07.022_bib0032","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1093\/eurheartj\/ehac184","article-title":"Pulmonary vascular disease in pulmonary hypertension due to left heart disease: pathophysiologic implications","volume":"43","author":"Omote","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2026.07.022_bib0033","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.jchf.2024.04.031","article-title":"Considerations in the diagnosis and management of pulmonary hypertension associated with left heart disease","volume":"12","author":"Ilonze","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.amjcard.2026.07.022_bib0034","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1161\/CIRCULATIONAHA.111.085761","article-title":"Pulmonary hypertension due to left heart disease","volume":"126","author":"Guazzi","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2026.07.022_bib0035","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/ehf2.15203","article-title":"Relaxin mimetic in pulmonary hypertension associated with left heart disease: design and rationale of Re-PHIRE","volume":"12","author":"Ufnal","year":"2025","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.amjcard.2026.07.022_bib0036","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01344-2024","article-title":"Pulmonary hypertension associated with left heart disease","volume":"64","author":"Maron","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.amjcard.2026.07.022_bib0037","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaf784.1290","article-title":"Rationale and design of the CADENCE trial: evaluating sotatercept in Cpc-PH secondary to HFpEF","volume":"46","author":"Gomberg-Maitland","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2026.07.022_bib0038","article-title":"Oral levosimendan for the treatment of pulmonary hypertension due to heart failure with preserved ejection fraction: rationale and design of the LEVEL trial","author":"Yaku","year":"2025","journal-title":"J Card Fail"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914926004765?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914926004765?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:32:12Z","timestamp":1791981132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914926004765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":38,"alternative-id":["S0002914926004765"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2026.07.022","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pulmonary Arterial Hypertension-Targeted Therapy for Pulmonary Hypertension Associated With Left Heart Disease: Bayesian and Frequentist Meta-Analysis of Randomized Controlled Trials","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2026.07.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}